GGrantIndex
Sort

64,565 grants matching drug discovery

A web-based platform for robust single-cell analysis, bulk data deconvolution and system-level analysis

$896,814
Cristiana Iosef · Advaita Corporation · R44 · FY2024 · GM

The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition

$896,761
Min Lu · Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2012 · AI

HIV RNase H natural product inhibitors

$896,645
Michael A Parniak · University Of Pittsburgh At Pittsburgh · U19 · FY2008 · AI

Rare Disease Translational Research

$896,627
Ewy Math㉠· National Center For Advancing Translational Sciences · ZIA · FY2025 · TR

Algorithms for the Discovery and Geometric-Matching of Hierarchical 3-D Templates of Functional Sites in Protein Structures

$896,527
Olivier Lichtarge · Baylor College Of Medicine · · FY2003 · BIO

CANCER DRUG DISCOVERY: CELL CYCLE CONTROL TARGETS

$896,446
University Of South Florida · P01 · FY2001 · CA

Cancer Gene Discovery to Identify Targetable Targets

$896,280
Carlo M Croce · Ohio State University · R35 · FY2019 · CA

SPORE in Bladder Cancer

$896,275
Jonathan Eric Rosenberg · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA

Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE

$896,274
Suresh S Ramalingam · Emory University · P50 · FY2024 · CA

Structure Analysis of Viral Assembly Mechanisms

$896,216
Mark Jay Yeager · University Of Virginia · R01 · FY2018 · GM

Lead optimization of Novel mGlu2 Negative Allosteric Modulators

$896,201
Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2016 · MH

Second Generation Small Molecule Inhibitors of Botulinum Neurotoxins

$896,077
Sina Bavari · Geneva Foundation · U01 · FY2013 · AI

Inhibitors of poxvirus enzymes as novel drugs

$896,022
Esteban Edward Mena · Lifepharms, Inc. · U01 · FY2009 · AI

BioGRID: An Open Integrated Resource for Biological Interaction Data

$895,794
Michael David Tyers · Sinai Health System · R01 · FY2011 · RR

The UIUC Neuroproteomics Center on Cell-Cell Signaling

$895,614
Jonathan V. Sweedler · University Of Illinois At Urbana-Champaign · P30 · FY2013 · DA

Shorter and more effective oral regimens for M. abscessus pulmonary disease

$895,538
Thomas Dick · Hackensack University Medical Center · R01 · FY2025 · AI

Novel therapeutics for fatty liver disease and type-II diabetes

$895,454
Sarah A Compton · Southeast Techinventures, Inc. · R44 · FY2015 · DK

Nuclear Factor-kappaB in Ovarian Cancer

$895,338
Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Targeting bacterial cell wall biogenesis for the development of novel antimicrob

$895,104
Thomas G Bernhardt · Harvard Medical School · U19 · FY2016 · AI

Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention

$895,058
Eric L Nuermberger · Johns Hopkins University · R01 · FY2017 · AI

Development of IMPDH-Targeted Drugs against Crytosporidium

$895,013
Lizbeth K. Hedstrom · Brandeis University · U01 · FY2009 · AI

Protease-resistant D-peptide Inhibitors of Ebola Virus Entry

$894,941
Brett D Welch · Navigen, Inc. · R44 · FY2017 · AI

Pharmacogenomics of Adrenal Suppression with Inhaled Corticosteroids (PhASIC)

$894,839
Amber Dahlin · Brigham And Women'S Hospital · R01 · FY2022 · HL

Preclinical Medications Discovery and Abuse Liability Testing for NIDA

$894,744
Matthew Walentiny · Virginia Commonwealth University · N01 · FY2025 · DA

Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies

$894,645
Steven H Olson · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · AG